samedan logo

 
 
spacer
home > ict > autumn 2019 > a landmark for life science professionals
PUBLICATIONS
International Clinical Trials

A Landmark for Life Science Professionals





DIA Europe 2020 is more than an annual meeting in Europe; it reflects DIA’s strategic initiatives across several thought leadership streams, including clinical development and operations, regulatory science and operations, value and access, medical affairs, and many others. However, it’s not enough to talk about thought leadership; at this stage, it’s important to ground it in what and who we are bringing to the table. First of all, being a ‘patients included’ event, we embed patient engagement in all content tracks, and Matthieu Boudes, PPP Coordinator at the European Patients’ Forum, has already spoken very highly of the importance of this meeting to patient representatives. He cited, as main reasons, “The 20 ICT l November 2019 ICT Spotlight DIA Europe 2020 will take place on 17-19 March in Brussels, at the start of a new fiveyear EU cycle. There's no better place or time to get valuable insights from key regulators and industry leaders from across the full spectrum of medicines development A Landmark for Life Science Professionals SP TLIGHT www.samedanltd.com l ICT 21 DIA Europe has become a landmark, must-attend event for life science professionals from across the entire drug development spectrum − from discovery to marketed use – to facilitate open collaboration by incorporating representatives from the full life science landscape. DIA ensures that industry, payers, patients, and regulators all have an equal voice. Thought-provoking worldwide issues will be deconstructed by acclaimed panellists representing multiple stakeholders from around the world in this growing ecosystem of life sciences. fantastic networking opportunity,” as well as “the outstanding programme and its diversity, covering all aspects of medicines development, from regulatory decisions, policy and digital innovation, to patient centricity”.

The importance of the latter point to pharmaceutical development and information sharing is in an upward trend, making it the central topic of a session chaired by PMDA International Programmes Director Junko Sato, where several heads of regulatory agencies from around the world will share their key findings on how to drive patient centricity, stemming from their clinical and regulatory experiences.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
About the company

DIA Europe has become a landmark, must-attend event for life science professionals from across the entire drug development spectrum − from discovery to marketed use – to facilitate open collaboration by incorporating representatives from the full life science landscape. DIA ensures that industry, payers, patients, and regulators all have an equal voice. Thought-provoking worldwide issues will be deconstructed by acclaimed panellists representing multiple stakeholders from around the world in this growing ecosystem of life sciences.
Print this page
Send to a friend
Privacy statement
News and Press Releases

A new anti-tumour treatment is one step closer to the clinic thanks to a new collaboration between In3Bio and 3P Biopharmaceuticals

[Pamplona, November 26 2019] 3P Biopharmaceuticals, a leading Contract Development and Manufacturing Organization (CDMO) specialized in process development and cGMP manufacturing of biologics, has been chosen by In3Bio, a UK based Biotech company, to collaborate in the development of a novel anti-tumour treatment.
More info >>

White Papers

The Importance of ADCC in Assessing Clinically Relevant Differences

Sartorius Stedim BioOutsource Ltd

Biosimilars have caused a revolution in the development of biologic drugs. The model for biosimilars is a combination of speed to market and low cost; these are fundamental to any biosimilar development project. The biosimilars pathway to approval is not always without difficulty, biosimilars are still relatively new, and as each new applicant is reviewed we are learning more and more about these molecules.
More info >>

 
Industry Events

Evolution Summit

4-7 May 2020, The Ritz Carlton, Fort Lauderdale, FL

The 22nd Evolution Summit is the premium forum bringing leading drug development executives and solution providers together. As an invitation-only event, taking place behind closed doors, the Summit offers an intimate environment for a focused discussion of key new drivers shaping drug development.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement